This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

ZELTIQ® Aesthetics Preliminary Injunction Against Clinipro In Spain Still On Record And In Full Force

ZELTIQ Aesthetics, Inc. (Nasdaq: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that the preliminary injunction originally granted by the Mercantile Court in Spain on May 4, 2012, still stands despite recent reports from Clinipro that it has been suspended.

The lawsuit against Clinipro in Spain alleges infringement of two European patents owned by Massachusetts General Hospital (MGH) and licensed exclusively to ZELTIQ. After hearing the petition for a preliminary injunction on May 4, the Mercantile Court in Spain granted ZELTIQ’s and MGH’s request thereby prohibiting Clinipro’s further importation, manufacture, distribution, offering for sale and sale of Clinipro’s LipoCryo device in Spain. The Mercantile Court subsequently scheduled a trial on the merits for a permanent injunction against Clinipro’s LipoCryo device to be held on September 18, 2012. While Clinipro has petitioned the Mercantile Court to suspend the preliminary injunction order, the Court determined that a suspension would not be granted unless Clinipro deposits the sum of €50,000 euros each month until the September trial in the case to cover ZELTIQ’s damages resulting from Clinipro’s ongoing patent infringement. As Clinipro has not deposited any funds, the preliminary injunction has not been, and cannot be suspended.

As a result, and under the existing Mercantile Court order, Clinipro is still banned from importation, manufacture, distribution, offering for sale and sale of Clinipro’s LipoCryo device in Spain. To continue to do so, as the company willingly acknowledged in its press release issued on July 3, 2012, only serves as an admission by Clinipro that it has been violating the Mercantile Court’s May 4 preliminary injunction order.

Mark Foley, interim President and Chief Executive Officer of ZELTIQ, commented, “It is unfortunate that Clinipro chose to publically issue a misleading statement and build on a campaign of market confusion. As a company, ZELTIQ is steadfast in its commitment to defend its intellectual property rights. We are confident that the Mercantile Court in Spain will again rule in our favor at the September trial as already demonstrated by the May 4 preliminary injunction order, and by the Court’s recent rejection of Clinipro’s petition to suspend the injunction without first depositing significant sums to cover ZELTIQ’s damages as a result of Clinipro’s ongoing patent infringement.”

Stock quotes in this article: ZLTQ 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs